These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34915789)

  • 1. Meeting report: an exploration into the scientific and regulatory aspects of pharmaceutical drug quality in the United States.
    Flavin BM; Happe LE; Hatton RC
    Expert Opin Drug Saf; 2022 Feb; 21(2):167-170. PubMed ID: 34915789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence and generic prescribing: an industrial view.
    Pidgen A
    J Pharm Pharmacol; 1996 Jan; 48(1):11-6. PubMed ID: 8722487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory status of medicinal products for human beings in the European Union. The role of generic products.
    Minghetti P
    Pharmacol Res; 1996; 34(1-2):3-7. PubMed ID: 8981548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

  • 5. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality?
    Marsh DA; Hoar ME
    Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WHO expert committee on specifications for pharmaceutical preparations. Fortieth report.
    WHO Expert Committee on Specifications for Pharmaceutical Preparations
    World Health Organ Tech Rep Ser; 2006; 937():1-461, back cover. PubMed ID: 16836287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.
    Tothfalusi L; Endrenyi L; Arieta AG
    Clin Pharmacokinet; 2009; 48(11):725-43. PubMed ID: 19817502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of generic ophthalmic drugs.
    Novack GD
    Ocul Surf; 2013 Jan; 11(1):54-6. PubMed ID: 23321360
    [No Abstract]   [Full Text] [Related]  

  • 9. Bioequivalence and interchangeability of narrow therapeutic range drugs. Canadian Society for Pharmaceutical Sciences discussion.
    Palylyk-Colwell E; Jamali F; Dryden W; Friesen E; Koven S; Mohamed I; Osmond B; Alessi-Severini S; Sheldon L; Sheldon R; Tam Y; Tsuyuki R; Zhanel G
    J Pharm Pharm Sci; 1998; 1(1):2-7. PubMed ID: 10942966
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA pharmaceutical quality oversight.
    Yu LX; Woodcock J
    Int J Pharm; 2015 Aug; 491(1-2):2-7. PubMed ID: 26027494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding Quality Paradigm Shifts in the Evolving Pharmaceutical Landscape: Perspectives from the USP Quality Advisory Group.
    Weitzel J; Pappa H; Banik GM; Barker AR; Bladen E; Chirmule N; DeFeo J; Devine J; Emrick S; Hout TK; Levy MS; Mahlangu GN; Rellahan B; Venema J; Workman W
    AAPS J; 2021 Oct; 23(6):112. PubMed ID: 34654974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organization
    World Health Organ Tech Rep Ser; 2005; 929():1-142, backcover. PubMed ID: 16353684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controls to Minimize Disruption of the Pharmaceutical Supply Chain During the COVID-19 Pandemic.
    Cundell T; Guilfoyle D; Kreil TR; Sawant A
    PDA J Pharm Sci Technol; 2020; 74(4):468-494. PubMed ID: 32467176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Allison G; Cain YT; Cooney C; Garcia T; Bizjak TG; Holte O; Jagota N; Komas B; Korakianiti E; Kourti D; Madurawe R; Morefield E; Montgomery F; Nasr M; Randolph W; Robert JL; Rudd D; Zezza D
    J Pharm Sci; 2015 Mar; 104(3):803-12. PubMed ID: 25830179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multinational medicines--ensuring drug quality in an era of global manufacturing.
    Okie S
    N Engl J Med; 2009 Aug; 361(8):737-40. PubMed ID: 19692686
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical Endpoint Bioequivalence Studies Are Needed: A Perspective From Brand Drugs.
    Krishna R; Kesisoglou F
    Clin Pharmacol Ther; 2019 Feb; 105(2):298-300. PubMed ID: 30456848
    [No Abstract]   [Full Text] [Related]  

  • 17. Emerging technology: A key enabler for modernizing pharmaceutical manufacturing and advancing product quality.
    O'Connor TF; Yu LX; Lee SL
    Int J Pharm; 2016 Jul; 509(1-2):492-498. PubMed ID: 27260134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Report suggests steps to improve safety of drug supply.
    Traynor K
    Am J Health Syst Pharm; 2011 Sep; 68(17):1570, 1574. PubMed ID: 21856799
    [No Abstract]   [Full Text] [Related]  

  • 19. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-ninth report.
    World Health Organization
    World Health Organ Tech Rep Ser; 2015; (992):1-210, back cover. PubMed ID: 26118121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organ Tech Rep Ser; 1999; 885():i-vi, 1-156. PubMed ID: 10352573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.